Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM604 Pilot Trial in ALS
NCT01854294Phase 2Completed
- Sponsor
- Genervon Biopharmaceuticals
- Start
- Aug 2013
- Primary completion
- Apr 2014
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of alirinetide in amyotrophic lateral sclerosis (ALS), sponsored by Genervon Biopharmaceuticals. Started Aug 2013; status: completed.
02
Drugs
alirinetide
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01854294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01854294.